

FOI 2501

15<sup>th</sup> July 2024**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

- **ALK Inhibitors (Alectinib - 3, Brigatinib - 0, Ceritinib - 0, Crizotinib - 0, Lorlatinib - 0)**
- **Amivantamab – 0**
- **Atezolizumab Monotherapy – 6**
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel – 0**
- **Dabrafenib + Trametinib - 0**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin – 2**
- **Durvalumab – 5**
- **Gemcitabine - 0**
- **Nitedanib + Docetaxel - 1**
- **Nivolumab – 1**
- **Osimertinib – 8**
- **Other EGFR Inhibitors (Afatinib - 0, Erlotinib – 1, Gefitinib - 0, Dacomitinib - 0, Mobocertinib – 1)**
- **Paclitaxel – with carbo - 8**
- **Pembrolizumab Monotherapy – 20**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) - 0**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) – 3**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin) – 3**
- **RET Inhibitors (Pralsetinib, Selpercatinib) - 0**
- **Sotorasib - 0**
- **Tepotinib - 0**
- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin - 0**
- **Other active systemic anti-cancer therapy - 0**
- **Palliative care only – not held**

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)